NCT03594682Unknown不适用
Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study
Beijing Chest Hospital0 个研究点目标入组 31 人开始时间: 2018年8月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 31
- 主要终点
- duration of treatment
研究概览
简要总结
The purpose of the study is to evaluate the safety and efficacy of two different administration methods of apatinib in NSCLC patients.
详细描述
- Aged ≥18；
- Locally advanced/metastatic non-small lung cancer (IIIb/IV) confirmed by pathology with measurable lesions；
- Patients with wild type EGFR/ALK must received two kinds of systemic chemotherapy before；Patients with EGFR mutation positive had experienced treatment failure with TKI in first line and Chemotherapy in second line ；
- ECOG：0-4；
- The subjects were treated with other drugs has been restored (NCI CTCAE version 4.0 class 1 or less), which accept nitroso urea or mitomycin interval 6 weeks or more; Accept other cytotoxic drugs, bevacizumab (Avastin) (except local palliative radiotherapy), radiotherapy or surgery four weeks or more. EGFR TKI ≥2 weeks; Main organs function is normal；
- Fertile woman must perform a pregnancy test (serum or urine) 7 days before screened, or voluntarily adopt proper methods of contraception during the observation period and 8 week after the last given apatinib. For man, surgical sterilization should be performed, or voluntarily adopt proper methods of contraception during the observation period and 8 week after the last given apatinib；
- Patients voluntarily entered the study and signed informed consent form (ICF).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Locally advanced/metastatic non-small lung cancer (IIIb / IV) confirmed by pathology with measurable lesions ；
- •Patients with wild type EGFR/ALK must received two kinds of systemic chemotherapy before；Patients with EGFR mutation positive had experienced treatment failure with TKI in first line and Chemotherapy in second line ；
- •The subjects were treated with other drugs has been restored (NCI CTCAE version 4.0 class 1 or less), which accept nitroso urea or mitomycin interval 6 weeks or more; Accept other cytotoxic drugs, bevacizumab (Avastin) (except local palliative radiotherapy), radiotherapy or surgery four weeks or more. EGFR TKI ≥2 weeks; Main organs function is normal；
- •Fertile woman must perform a pregnancy test (serum or urine) 7 days before screened, or voluntarily adopt proper methods of contraception during the observation period and 8 week after the last given apatinib. For man, surgical sterilization should be performed, or voluntarily adopt proper methods of contraception during the observation period and 8 week after the last given apatinib；
- •Patients voluntarily entered the study and signed informed consent form (ICF).
排除标准
- •brain MRI, CT or venography confirmed that there are brain hemorrhage symptoms；
- •Tumor invade big vessels or close to big vessels (less than 5mm)；
- •Patients with uncontrollable hypertension (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg, despite optimal drug therapy).；
- •Patients with with grade Ⅱ myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male ≥ 450 ms, female ≥470 ms)；
- •Abnormal coagulation (INR>1.5 or PT>ULN+4, or APTT>1.5 ULN), bleeding tendency or receiving coagulation therapy
- •Urine protein≥++, or urine protein in 24 hours≥1.0g
- •CTCAE 2 degrees or more peripheral neuropathy, except the trauma;
- •Unhealed bone fracture or wound for long time；
- •Patients who received systemic antibiotic treatment of serious infections;
- •Decompensated diabetes or high dose of glucocorticoid treatment other banned disease;
- •Patients with active hepatitis B virus or hepatitis c virus infection；
- •Patients with obvious factors affecting absorption of oral drugs, such as difficulties in swallowing, chronic diarrhea and intestinal obstruction, etc.
- •Received big surgery, had bone fracture or ulcer in 4 weeks.
- •Within 6 weeks before random severe weight loss (> 10%);
- •Patients who experienced bleeding symptoms of clinical significance within 3 months before screening, or with confirmed bleeding tendency such as hemorrhage of digestive tract, hemorrhagic gastric ulcer, baseline occult blood in stool ++ and above, or vasculitis, etc；
- •Random 12 months before the artery/vein thrombosis events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.；
- •Known history of hypersensitivity to apatinib or any of it components.
研究组 & 干预措施
dose titration group
Experimental
First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
干预措施: Intervention/treatment (Other)
non-titration group
Active Comparator
Patients were given 750mg qd apatinib until disease progression or intolerance
干预措施: Intervention/treatment (Other)
结局指标
主要结局
duration of treatment
时间窗: two years
time from take apatinib to withdrawal from experiment due to adverse reaction of apatinib
次要结局
未报告次要终点
研究者
Ying Hu
Vice Director,Department of oncology
Beijing Chest Hospital
相似试验
Unknown
2 期
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric CancerMetastatic Gastric CancerNCT03154983Zhou Fuxiang48
已完成
2 期
Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentEsophageal Squamous Cell CarcinomaNCT02976896Yuhong Li43
Unknown
3 期
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung CancerSmall Cell Lung CancerNCT03651219Beijing Chest Hospital90
已完成
2 期
Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular GoiterMultinodular GoiterNCT00454220Genzyme, a Sanofi Company96
Unknown
2 期
Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical ResectionHepatocellular CarcinomaNCT03839550Cancer Institute and Hospital, Chinese Academy of Medical Sciences200